Frankfurt
26.11.25 | 08:03
0,043 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,041 | 0,064 | 12:55 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.11. | Ventripoint Diagnostics Ltd (2): Ventripoint arranges $542,591 debt settlement | 1 | Stockwatch | ||
| 06.11. | Ventripoint Diagnostics Ltd.: Ventripoint Announces Debt Settlement Agreements | 2 | TheNewswire | ||
| 29.10. | Ventripoint Diagnostics Ltd (2): Ventripoint to test AI-enhanced echocardiography | 1 | Stockwatch | ||
| 29.10. | Ventripoint Diagnostics Ltd.: Ventripoint Diagnostics and Providence Health Care Ventures Announce Collaboration to Validate AI-Enabled Cardiac Imaging at St. Paul's Hospital | 1 | TheNewswire | ||
| 24.10. | Ventripoint Diagnostics Ltd (2): Ventripoint talks VMS+, sales expansion, partnerships | 2 | Stockwatch | ||
| 24.10. | Ventripoint Diagnostics Ltd.: Ventripoint Provides Corporate Update and Announces Shareholder Teleconference | 1 | TheNewswire | ||
| 14.10. | Ventripoint Diagnostics Ltd.: Ventripoint Announces Closing of Second and Final Tranche of Non-Brokered Convertible Debenture Units Private Placement | 1 | TheNewswire | ||
| VENTRIPOINT DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 03.10. | Ventripoint Diagnostics Ltd (2): Ventripoint to extend, increase debenture financing | 2 | Stockwatch | ||
| 03.10. | Ventripoint Diagnostics Ltd.: Ventripoint Announces Extension and Up Size of Non-Brokered Convertible Debenture Unit Private Placement | 2 | TheNewswire | ||
| 19.09. | Ventripoint Diagnostics Ltd (2): Ventripoint Diagnostics completes annual quality audit | 1 | Stockwatch | ||
| 19.09. | Ventripoint Diagnostics Ltd.: Ventripoint Announces Successful Completion of Key Quality Audits | 2 | TheNewswire | ||
| 03.09. | Ventripoint Diagnostics Ltd.: Ventripoint Announces Closing of First Tranche of Non-Brokered Convertible Debenture Unit Private Placement | 1 | TheNewswire | ||
| 27.08. | Ventripoint Diagnostics Ltd (2): Ventripoint arranges $5M financing of debenture units | 1 | Stockwatch | ||
| 26.08. | Ventripoint Diagnostics Ltd.: Ventripoint Announces Non-Brokered Convertible Debenture Units Private Placement and Share Issuance | 2 | TheNewswire | ||
| 19.08. | Ventripoint Diagnostics Ltd (2): Ventripoint appoints Brown as program director | 1 | Stockwatch | ||
| 18.08. | Ventripoint Diagnostics Ltd.: Ventripoint Diagnostics Appoints Thomas Brown as Director of Congenital Heart Defect Program | 1 | TheNewswire | ||
| 15.08. | Ventripoint Diagnostics Ltd.: Ventripoint Diagnostics Launches Targeted Congenital Heart Defect Marketing Program, Setting Stage for Multi-Segment Growth | 1 | TheNewswire | ||
| 13.08. | CEO.CA Technologies Ltd.: CEO.CA's Inside the Boardroom: Cardiac MRI Alternative Gets FDA Nod - Ventripoint CEO on U.S. and China Sales Plans | 344 | Newsfile | Toronto, Ontario--(Newsfile Corp. - August 13, 2025) - CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mining... ► Artikel lesen | |
| 29.07. | Ventripoint Diagnostics Ltd (2): Ventripoint receives purchase order from Lishman | 1 | Stockwatch | ||
| 28.07. | Ventripoint Diagnostics Ltd.: Lishman Global Places First Order for Ventripoint's VMS+ Technology | 1 | TheNewswire |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ATOSSA THERAPEUTICS | 0,667 | +0,45 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update | Company reports progress to file planned IND for (Z)-endoxifen in mBC with CRO selection and streamlined development programs for potential 2026-NDA enabling activities... ► Artikel lesen | |
| TANDEM DIABETES | 18,860 | -0,11 % | Tandem Diabetes Care beruft Sandra Beaver in den Verwaltungsrat | ||
| VERU | 2,390 | 0,00 % | Veru Inc.: Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress | --Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal... ► Artikel lesen | |
| MOLINA HEALTHCARE | 128,65 | +1,34 % | Insider Selling: Richard M Schapiro Unloads $51K Of Molina Healthcare Stock | ||
| CLOVER HEALTH INVESTMENTS | 2,092 | +0,14 % | Clover Health Investments, Corp.: Clover Health Announces Chelsea Clinton to Step Down from Board Following Eight Years of Service | WILMINGTON, Del., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover," "Clover Health" or the "Company") today announced that Chelsea Clinton, the longest-serving... ► Artikel lesen | |
| COGNETIVITY NEUROSCIENCES | 0,015 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.06.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 02.06.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.06.2025ISIN NameCA19243C1005 COGNETIVITY... ► Artikel lesen | |
| SEMLER SCIENTIFIC | 17,200 | -2,27 % | Strive, Inc. (Nasdaq: ASST) and Semler Scientific, Inc. (Nasdaq: SMLR) Announce Bitcoin Treasury Merger in All-Stock Transaction | DALLAS, TX and CAMPBELL, CA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Strive, Inc. ("Strive") entered into a definitive agreement to acquire Semler Scientific, Inc. ("Semler Scientific") in an all-stock... ► Artikel lesen | |
| SOMNIGROUP INTERNATIONAL | 77,00 | -0,65 % | Dividendenbekanntmachungen (20.11.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALLIENT INC US0193301092 0,03 USD 0,0259 EUR APPLIED MATERIALS INC US0382221051 0,46 USD 0,3986 EUR APPLIED MATERIALS INC CDR CA03822G1046 0... ► Artikel lesen | |
| SHL TELEMEDICINE | - | - | SHL TELEMEDICINE LTD - 6-K, Report of foreign issuer | ||
| SINTX TECHNOLOGIES | 3,690 | 0,00 % | SiNtx Technologies, Inc.: SINTX Technologies erhält FDA-Zulassung für SINAPTIC Fuß- und Sprunggelenk-Implantatsystem | Das von der FDA zugelassene und in den USA hergestellte Implantatsystem positioniert SINTX für den Eintritt in den milliardenschweren US-Markt
SALT LAKE CITY, Utah, Oct. 20, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| SMILEDIRECTCLUB | - | - | Align Technology Settles Antitrust Lawsuit Over SmileDirectClub Deal for $31.75 Million | ||
| NEURONETICS | 1,186 | -1,00 % | Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan | Delivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue growth versus Q3 2024 Generated Greenbrook clinic revenue of $21.8 million in Q3 2025, an increase of... ► Artikel lesen | |
| GENEDX | 167,52 | 0,00 % | GeneDx auf der Jefferies London Konferenz: Strategische Expansion in der Pädiatrie | ||
| PROGYNY | 26,770 | 0,00 % | Progyny, Inc.: New Men's Health Research from Progyny Challenges Conventional Beliefs about Fertility Knowledge and Action | ||
| ALIGNMENT HEALTHCARE | 19,150 | 0,00 % | Alignment Healthcare stock rating upgraded by JPMorgan to Overweight |
VENTRIPOINT DIAGNOSTICS LTD gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 0,043 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VENTRIPOINT DIAGNOSTICS LTD finden Sie auf Wallstreet Online.